Key Facts
- Gene editing changes DNA in targeted cells. It differs from gene therapy that adds genetic material without changing the patient’s existing DNA.
- In the United States, the FDA lists Casgevy, a CRISPR-based treatment, for eligible patients aged 2 and older with recurrent sickle cell pain crises or transfusion-dependent beta-thalassemia. The younger-age indication was approved in 2026.
- Casgevy edits a patient’s blood-forming stem cells outside the body. Treatment also requires intensive preparatory chemotherapy and follow-up; it is not a simple injection.
- In 2025, clinicians gave an infant with a rare metabolic disorder a personalized, experimental base-editing treatment. The early response was encouraging, but one case cannot establish long-term safety or a treatment pathway for all rare diseases.
- Researchers are testing editing for blood cancers and high cholesterol. Those investigational approaches should not be confused with approved treatments.
- The central barriers to wider use remain safe delivery, unintended edits, long-term evidence, manufacturing and equitable access.
Gene editing has reached a consequential point in medicine: some patients can already receive an approved CRISPR treatment, while experimental teams are testing whether targeted changes to DNA could address diseases that have long been difficult to treat.
The most established example is Casgevy, used in eligible U.S. patients with certain severe inherited blood disorders. Its approved age range now extends to children as young as 2. Meanwhile, a personalized treatment created for one infant and early studies in cancer and cardiovascular disease point toward wider possibilities. None shows that gene editing can yet cure every genetic disorder, or that an encouraging result in a small study will hold up over decades.
The question is shifting from whether scientists can edit human cells to whether they can do so reliably, safely and at a scale that health systems can support.
How gene editing works
DNA contains instructions that help cells develop and function. A harmful change in those instructions can contribute to disease. Gene-editing tools aim to make a targeted change: cutting DNA at a selected site, altering a DNA letter, or changing how a gene is controlled.
CRISPR-Cas9 is the best-known approach, but it is not the only one. Base editing, used in the infant’s experimental treatment, is designed to change particular DNA letters without relying on the same type of double-strand cut. Different tools suit different biological problems.
“Gene editing” is also not a synonym for every gene therapy. Some gene therapies supply an additional functioning gene rather than edit a patient’s existing sequence. That difference matters when evaluating a headline about a new treatment: readers should ask what was changed, which cells were targeted and whether the reported outcome has been demonstrated in patients.
There are two broad delivery routes. In an ex vivo treatment, clinicians remove cells, edit them outside the body, test and prepare them, then return them to the patient. In an in vivo treatment, an editing system is delivered into the body to reach cells in a particular tissue. The latter may avoid a cell-transplant procedure, but getting the editor to the right cells, and limiting its effects elsewhere, is a major challenge.
Today’s therapeutic work generally concerns a patient’s body cells. Such changes are not intended to be inherited by children. Editing embryos or reproductive cells would raise separate safety and ethical issues. The World Health Organization has urged strong governance and warned against moving heritable human genome editing prematurely into clinical use.
What approved treatment has proved
Casgevy is a milestone because its benefit has been tested in patients and reviewed by a regulator. The FDA first approved it for eligible people aged 12 and older with sickle cell disease and later for transfusion-dependent beta-thalassemia; its current U.S. indications extend to patients aged 2 and older. The 2026 pediatric expansion relied in part on evidence from older patients and product characteristics, with studies in younger children ongoing. Approval for younger ages should not be mistaken for decades of pediatric follow-up.
Sickle cell disease can cause severe episodes when abnormally shaped red blood cells obstruct blood flow. Beta-thalassemia can leave patients dependent on regular blood transfusions. Casgevy edits a patient’s own blood-forming stem cells so they produce more fetal hemoglobin, which can reduce the effects of these disorders. It does not directly rewrite every copy of the original disease-causing mutation.
In the evidence supporting the original sickle cell approval, 29 of 31 evaluable patients experienced at least 12 consecutive months without a severe vaso-occlusive crisis. That is a substantial result for the people in that analysis. It is not a promise that every recipient will have the same outcome, nor proof of lifelong protection.
Treatment is demanding. Clinicians collect stem cells, arrange specialized manufacturing and give chemotherapy to clear space in the bone marrow before infusing the edited cells. The FDA’s prescribing information describes risks associated with this process, including low blood counts, bleeding and infection. Patients require care at qualified treatment centers and long-term monitoring.
Those demands explain why approval does not automatically translate into easy access. A family may need to weigh disease severity, current treatment options, time away from home, medical risks and coverage rules. FDA authorization applies to the United States; other countries make their own regulatory and funding decisions.
What the newer research shows
The 2025 treatment of an infant with carbamoyl-phosphate synthetase 1, or CPS1, deficiency offers a glimpse of more individualized medicine. The rare condition disrupts the body’s ability to dispose of nitrogen, allowing dangerous ammonia levels to build up. Researchers designed a base editor for the child’s specific mutation and delivered it to the liver using lipid nanoparticles. The process from diagnosis to treatment took about six months, according to the U.S. National Institutes of Health.
After treatment, the child tolerated more dietary protein and needed less medication to control ammonia, the NIH reported. Those observations are encouraging. But the published experience involved one patient and short early follow-up; it does not establish how durable the benefit will be or whether the approach can be manufactured affordably for many different mutations.nih+1
Cancer researchers are pursuing another strategy. In a study reported by Washington University School of Medicine, donor stem cells were edited to remove a protein called CD33 before transplantation into 30 adults with aggressive blood cancers. The edited cells engrafted in all participants by day 28, potentially allowing a subsequent treatment to target CD33 on cancer cells while sparing the new blood-forming cells.
That is an early-stage finding, not proof of a broadly effective cancer therapy. Seven participants died during the study, including from disease progression and transplant-related causes. The patients were seriously ill, but those outcomes must be considered alongside the successful engraftment result.
Early human studies are also examining whether editing genes involved in cholesterol regulation could produce lasting reductions in LDL cholesterol. A laboratory or blood-test improvement is not yet proof that a treatment prevents heart attacks or strokes. Trials must establish who benefits, how durable the change is and whether the risks are acceptable compared with available care.
The limits behind the promise
Precision does not mean zero risk. An editor might make an unintended change, reach the wrong tissue or fail to edit enough cells to produce a useful effect. Some procedures introduce risks unrelated to the edit itself, as Casgevy’s preparatory chemotherapy illustrates. Researchers and regulators therefore need both biological testing and years of clinical follow-up.
Cost and capacity matter, too. Collecting and editing cells for each patient requires specialized facilities; designing a bespoke therapy for one mutation presents a different manufacturing problem. The recent personalized infant case demonstrates scientific feasibility, not a ready-made system for treating every person with an ultra-rare disease.
The next phase will be judged less by the number of conditions named in research announcements than by larger trials, transparent safety data and whether approved therapies reach patients who could benefit. A “one-time” intervention may still entail months of care and years of monitoring.
What This Means for Consumers
Gene editing is already a treatment option for some people, but most proposed uses remain experimental. A patient or family reading about a new study should first determine whether it describes an FDA-approved indication, a registered clinical trial or an individual case.
Useful questions for a specialist include: What outcome has been demonstrated in people? How many patients were studied, and for how long? What preparation and follow-up are required? What are the known complications and the unresolved long-term risks? Are established treatments available, and how do their benefits and burdens compare?
For U.S. patients, an FDA approval identifies the conditions and ages covered by that authorization; it does not resolve insurance coverage or determine whether a treatment is right for one person. Readers outside the United States should check their own regulator and health system rather than assume a U.S. approval applies locally.
The most durable lesson is neither that gene editing is a universal cure nor that it is too new to matter. It has produced meaningful results in specific settings. Expanding those results responsibly will require evidence as careful as the underlying science.
FAQs
Is gene editing the same as gene therapy?
No. Gene editing makes a targeted change to DNA. Gene therapy is a broader category that can include delivering a working gene without changing the existing sequence. Some treatments involve both concepts.
What diseases can CRISPR treat now?
In the United States, the FDA lists the CRISPR-based treatment Casgevy for eligible patients aged 2 and older with recurrent sickle cell crises or transfusion-dependent beta-thalassemia. Other CRISPR applications discussed here remain investigational.
Does gene editing permanently cure a disease?
It may produce a durable benefit, but permanence depends on the treatment and long-term results. Early trial success does not guarantee lifelong benefit or rule out late complications.
Can gene editing prevent heart disease?
Researchers are testing edits that lower cholesterol-related measures. It has not yet been established that those experimental interventions safely prevent heart attacks or strokes.
Are edited genes passed to children?
The approved treatment discussed here edits a patient’s body cells and is not intended to alter reproductive cells. Heritable genome editing is a separate area subject to substantial scientific and ethical concern.